Evaluation of the effect of empagliflozin in combination with pioglitazone on fatty liver disease

Not Applicable

• Conditions: Fatty liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20240208060939N1
• Lead Sponsor: Artesh University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Having type 2 diabetes and fatty liver at the same time

Exclusion Criteria

Active or chronic hepatitis, cirrhosis and biliary disease
Class III and IV heart failure
Renal dysfunction GFR<45

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AST,ALT. Timepoint: 0, 24 Week after. Method of measurement: Laboratory.;CAP score. Timepoint: 0, 24 Week after. Method of measurement: Sonography/Fibro Scan.;Nafld fibrosis score. Timepoint: 0, 24 Week after. Method of measurement: D fibrosis score = -1.675+0.037-age(years)+0.094-BMI(kg/m^2)+1.13× IFG/diabetes(yes=1,no=0)+0.99×AST/ALTratio-0.013×PLT- 0.66×albumin.;APRI ratio. Timepoint: 0, 24 Week after. Method of measurement: AST/PLT ratio.;FIB-4 index. Timepoint: 0, 24 Week after. Method of measurement: Age (years)×AST (U/L)/[PLT(109/L)×ALT1/2 (U/L)].